Advertisement
Advertisement

RGNX

RGNX logo

REGENXBIO Inc.

11.14
USD
Sponsored
-0.46
-3.97%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

11.21

+0.07
+0.63%

RGNX Earnings Reports

Positive Surprise Ratio

RGNX beat 16 of 40 last estimates.

40%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$51.28M
/
-$0.83
Implied change from Q3 25 (Revenue/ EPS)
+72.47%
/
-30.83%
Implied change from Q4 24 (Revenue/ EPS)
+141.72%
/
-17.82%

REGENXBIO Inc. earnings per share and revenue

On Nov 06, 2025, RGNX reported earnings of -1.20 USD per share (EPS) for Q3 25, beating the estimate of -1.33 USD, resulting in a 9.88% surprise. Revenue reached 29.73 million, compared to an expected 24.61 million, with a 20.83% difference. The market reacted with a -3.79% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.83 USD, with revenue projected to reach 51.28 million USD, implying an decrease of -30.83% EPS, and increase of 72.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, REGENXBIO Inc. reported EPS of -$1.20, beating estimates by 9.88%, and revenue of $29.73M, 20.83% above expectations.
The stock price moved down -3.79%, changed from $11.61 before the earnings release to $11.17 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 14 analysts, REGENXBIO Inc. is expected to report EPS of -$0.83 and revenue of $51.28M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement